Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR)(NYSE:SNY) have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments …
In a research report issued today, Brean Capital analyst Jonathan Aschoff offered some commentary on Regeneron Pharmaceuticals Inc (NASDAQ:REGN), following the news that Regeneron’s Praluent, the …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that the European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection …
Managing cholesterol is a private, emotional fight against a condition that cannot be seen or felt.1 Now, a new film highlights individuals around …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that Bayer HealthCare’sJapanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA® (aflibercept) Injection by the Ministry of Health, Labour and …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced the winners of the third annual Regeneron Prize for Creative Innovation, an award designed to acknowledge, reward and foster talented …
In a research report issued today, Piper Jaffray analyst Edward Tenthoff weighed in with a few insights on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) following Avalanche’s …
RBC Capital analyst Adnan Butt was out pounding the table with Regeneron Pharmaceuticals Inc (NASDAQ:REGN), reiterating an Outperform rating on the stock and boosting the price …
In a research report released Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) with a $525 price target, …
